Table 5.
Parameter | Disease stratum Treatment group |
Decrease | Baseline measurement | Lowest post-baseline measurement | Assessment at which lowest measurement recorded |
---|---|---|---|---|---|
Oxygen saturation, greatest % decrease | Asthma stratum | ||||
Placebo | 15.2% | 98.7% | 83.5% | Minute 5 | |
Regadenoson | 12.4% | 97.9% | 85.5% | Minute 30 | |
COPD stratum | |||||
Placebo | 14.4% | 95.2% | 80.8% | Hours 3–7 | |
Regadenoson | 12.7% | 98.2% | 85.5% | Minute 30 | |
FEV1, greatest % decrease | Asthma stratum | ||||
Placebo | 0.74 L (32.9%) | 2.25 L | 1.51 L | Hour 2 | |
Regadenoson | 0.64 L (34.4%) | 1.86 L | 1.22 L | Minute 15 | |
COPD stratum | |||||
Placebo | 0.50 L (29.9%) | 1.67 L | 1.17 L | Hour 2 | |
Regadenoson | 0.78 L (44.6%) | 1.75 L | 0.97 L | Minute 5 | |
FEV1, greatest absolute decrease | Asthma stratum | ||||
Placebo | 1.06 L (32.3%) | 3.28 L | 2.22 L | Minute 15 | |
Regadenoson | 1.11 L (33.1%) | 3.35 L | 2.24 L | Minute 15 | |
COPD stratum | |||||
Placebo | 0.55 L (28.8%) | 1.91 L | 1.36 L | Minute 5 | |
Regadenoson | 0.79 L (30.7%) | 2.57 L | 1.78 L | Minute 15 |
COPD, Chronic obstructive pulmonary disease; FEV 1, forced expiratory volume in 1 second.